Financials
Financial year 2025
Revenue
€ 294.3 million
▲ 106% vs 2024
Profit
Growing€ 11.5 million
▲ 88% vs 2024
Debts
Normal€ 59.3 million
▲ 88% vs 2024
Eli Lilly Benelux from Brussel, company number BE0406754454, closed financial year 2025 with a result of € 11.5 million after tax. For that financial year Eli Lilly Benelux recorded revenue of € 294.3 million and equity of € 20.4 million. Compared with financial year 2024, the result moved from € 6.1 million to € 11.5 million. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
What happened at Eli Lilly Benelux?
What happened at Eli Lilly Benelux in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 11.5 million (▲ 88% vs 2024). Source: NBB ↗
- Sandrine FERRIERE stepped down as director. NBB
- Frederic CLAIS stepped down as director. NBB
- Sandrine FERRIERE became a director. NBB
- Frederic CLAIS became a director. NBB
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
In short
From € 6.5 million profit in 2021 to € 11.5 million profit in 2025.
Paid € 10.6 million in corporate taxes since 2021.
Best year ever: 2025, with € 11.5 million profit.
Paid out € 28 million in dividends to the owners in total.
A new publication or filing at Eli Lilly Benelux? We notify you, reason included.
Follow Eli Lilly BeneluxNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by ELI LILLY NETHERLAND BV (100%) and ELI LILLY EUROPEAN CLINICAL TRIALS SERVICES SA (0%).
Directors
According to the 2025 annual accounts
Sandrine FERRIERE
Director
since 2020 · until 2026
Frederic CLAIS
Director
since 2020 · until 2026
Shareholders
ELI LILLY NETHERLAND BV
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Markiesstraat 1
1000 Brussel
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 21 companies are registered at this address.
Euronext Brussels
€ 32.5 million revenue · 2025
Fonds tot bevordering van het industrieel onderzoek in Vlaanderen
Föderale Nuklearkontrollbehörde
€ 34.4 million revenue · 2025
FESTIVAL VAN VLAANDEREN INTERNATIONAAL BRUSSEL - EUROPA
€ 738,871 gross margin · 2025
Plan International Belgium
+16 more
Details
- Company number
- 0406.754.454
- VAT number
- BE 0406.754.454
- Registered office
- Markiesstraat 1, 1000 Brussel
- Names & denominations
- Eli Lilly Benelux
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 June 1969
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen